The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

ulthera.com

Executives

5

Board of Directors

3

Ulthera Board of Directors

3 Board of directors

Ulthera has 3 board of directors, including Chip Linehan.

Name

Firm

Work History

Other Seats

Chip Linehan

Investing Area: Healthcare &#65279

Ulthera

David Porter

David has over 30 years of experience in private equity and investment banking. He has advised on a wide range of companies and at Apposite, he serves or has served on the Boards of MC Care Holdings, NIMGenetics, Swanton Care, CancerPartnersUK, Ulthera, Zonare and Xthetix. Prior to co-founding Apposite in 2006, David worked on a number of large leveraged buy-outs with Nomura’s Principal Finance Group. He then founded and headed Nomura International’s healthcare investment and corporate finance groups. David has been the CEO of a number of companies, including CLF Municipal Bank, an authorised bank. David is very involved in the UK healthcare industry, having served as a member of the UK government’s Health Reform Group looking at reforms to the provision of healthcare to NHS patients and on the London Health Commission. David has a degree in Chemistry from Oxford University.

Ulthera

Justin Klein

Ulthera

Name

Chip Linehan

David Porter

Justin Klein

Firm

Work History

Investing Area: Healthcare &#65279

David has over 30 years of experience in private equity and investment banking. He has advised on a wide range of companies and at Apposite, he serves or has served on the Boards of MC Care Holdings, NIMGenetics, Swanton Care, CancerPartnersUK, Ulthera, Zonare and Xthetix. Prior to co-founding Apposite in 2006, David worked on a number of large leveraged buy-outs with Nomura’s Principal Finance Group. He then founded and headed Nomura International’s healthcare investment and corporate finance groups. David has been the CEO of a number of companies, including CLF Municipal Bank, an authorised bank. David is very involved in the UK healthcare industry, having served as a member of the UK government’s Health Reform Group looking at reforms to the provision of healthcare to NHS patients and on the London Health Commission. David has a degree in Chemistry from Oxford University.

Other Seats

Ulthera

Ulthera

Ulthera

Ulthera Management Team

5 Team Members

Ulthera has 5 executives. Ulthera's current Chief Financial Officer is Gregory D Waller.

Name

Work History

Title

Status

Gregory D Waller

Chief Financial Officer

Current

Matthew E. Likens

President

Former

Brian O'Connor

President

Former

James G Atkinson

Executive Vice President

Former

Jim Atkinson

Executive Vice President

Former

Name

Gregory D Waller

Matthew E. Likens

Brian O'Connor

James G Atkinson

Jim Atkinson

Work History

Title

Chief Financial Officer

President

President

Executive Vice President

Executive Vice President

Status

Current

Former

Former

Former

Former

You May Also Like

A
Affinergy

Affinergy develops site-specific biological delivery systems using biofriendly binders that can selectively adhere to proteins, cells and other biomaterial surfaces. Affinergy's multifunctional delivery systems offer unprecedented opportunities to target therapeutic delivery, functionalize medical devices, and enable a variety of diagnostic and biosensor applications. Affinergy is a Duke University spin-out company being incubated by BD (Becton, Dickinson and Company) and is headquartered in Research Triangle Park, NC. IDEA Fund Partners was an investor in the company's Series A financing.

Akonni Biosystems Logo
Akonni Biosystems

Akonni Biosystems is a molecular diagnostics (MDx) company that develops, manufactures, and markets integrated molecular diagnostic systems.

Q
QI2

UIQI2 is designed to develop and utilize in-house processes and technical infrastructure for the conduct of imaging-based multi-center trials. The main objective is to develop infrastructure within the University of Iowa, which will support the pulmonary imaging portion of government and industry-based multi-center trials. The target audience is government and corporate sponsored multi-centered pre-clinical and clinical trials; specifically the Pharmaceutical and Device sectors of the medical industry as well as large NIH trials.

I
Integrated Nano-Technologies

Integrated Nano-Technologies specializes in developing creative solutions for diagnostic sample processing, and provides field personnel with fast, accurate test results that can improve biological identification.

F
Focal

Focal develops, manufactures and commercializes synthetic, absorbable, liquid surgical sealants based on the company's polymer technology. The company's FocalSeal-L and FocalSeal-S surgical sealant products are currently being developed for use inside the body to seal leaks resulting from lung, neurological, cardiovascular and gastrointestinal surgery.

Sober Steering Logo
Sober Steering

Sober Steering develops transdermal technologies as means for detecting driver intoxication.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.